Identification of alpha3, alpha4, and alpha5 chains of type IV collagen as alloantigens for Alport posttransplant anti-glomerular basement membrane antibodies.
BACKGROUND
Alport syndrome is a hereditary disorder of basement membranes especially affecting the kidneys, ears, and eyes. Some patients who undergo renal transplantation lose their kidneys as a result of posttransplant anti-glomerular basement membrane (anti-GBM) disease.


METHODS
In the present study, we analyzed serum from 21 unselected Alport patients who underwent renal transplantation. Eleven samples were from patients without posttransplant anti-GBM nephritis, and 10 were from patients with this disease.


RESULTS
Thirteen serum samples [10 alport posttransplant nephritis serum (APTN) and three Alport posttransplant serum (APT)] revealed linear binding to the GBM by indirect immunofluorescence. By using direct ELISA and immunoblotting with GBM constituents and type IV collagen NC1 domains from bovine, human, and recombinant sources, we detected anti-GBM antibodies in all Alport patients in varying titers. Five samples showed specific reactivity to the alpha3 chain, four to the alpha5 chain, six to both alpha3 and alpha5 chains, one to the alpha3 and alpha4 chains, and two to the alpha3, alpha4, and alpha5 chains of type IV collagen. The varied spectrum of reactivities was present equally in nephritic and non-nephritic sera. Ten control samples from non-Alport transplant patients did not exhibit specific binding to the GBM.


CONCLUSIONS
These results suggest that the absence of alpha3, alpha4, and alpha5 chains of type IV collagen in the Alport kidney leads to alloantibodies in all Alport patients who receive transplants, irrespective of whether they develop nephritis or not. Although all Alport transplant patients develop this humoral response, only a select few develop anti-GBM disease. We suggest that this difference could be attributable to a genotypic effect on the ability of some individuals to launch a cell-mediated immune response.
Kalluri
R
R
Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA. rkalluri@Caregroup.Harvard.edu
Torre
A
A
Shield
C F
CF
Zamborsky
E D
ED
Werner
M C
MC
Suchin
E
E
Wolf
G
G
Helmchen
U M
UM
van den Heuvel
L P
LP
Grossman
R
R
Aradhye
S
S
Neilson
E G
EG
D000818:Animals; D000906:Antibodies / Q000097:blood; D001485:Basement Membrane / Q000276:immunology* / Q000378:metabolism; D002417:Cattle; D003094:Collagen / Q000276:immunology*; D003429:Cross Reactions / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D015151:Immunoblotting; D007074:Immunoglobulin G / Q000378:metabolism; D007519:Isoantigens / Q000097:blood*; D007678:Kidney Glomerulus / Q000276:immunology* / Q000378:metabolism; D016030:Kidney Transplantation / Q000276:immunology*; D009394:Nephritis, Hereditary / Q000276:immunology*; D011183:Postoperative Complications / Q000276:immunology; D011485:Protein Binding; D013997:Time Factors
D000906:Antibodies; D007074:Immunoglobulin G; D007519:Isoantigens; D003094:Collagen